T-CELL LYMPHOMA
Clinical trials for T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare skin cancer: targeted drug shows promise in chinese patients
Disease control CompletedThis study tested the drug brentuximab vedotin in 10 Chinese adults with a rare type of skin lymphoma called CD30-positive cutaneous T-cell lymphoma. The goal was to see if the drug could shrink or clear the cancer and to check for long-term side effects. Participants received th…
Matched conditions: T-CELL LYMPHOMA
Phase: PHASE4 • Sponsor: Takeda • Aim: Disease control
Last updated May 17, 2026 06:44 UTC
-
New drug combo shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-stage study tested a new drug called PRT2527, alone or combined with other drugs (zanubrutinib or venetoclax), in 86 people with blood cancers that returned or didn't respond to standard treatments. The main goals were to find a safe dose and check for side effects. Re…
Matched conditions: T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for Hard-to-Treat lymphoma? drug shows promise in small study
Disease control CompletedThis study tested a drug called brentuximab vedotin in 23 people with a rare type of T-cell lymphoma that had stopped responding to or returned after prior chemotherapy. The drug targets a marker called CD30, even when levels are very low. The main goal was to see if the drug cou…
Matched conditions: T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Deepa Jagadeesh • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Gene-Edited immune cells take on Hard-to-Treat blood cancers
Disease control CompletedThis study tested a new treatment called CTX131 for adults with blood cancers (lymphoma or leukemia) that came back or didn't respond to standard therapy. CTX131 uses CRISPR gene editing to create donor immune cells that target a protein called CD70 on cancer cells. The goal was …
Matched conditions: T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:42 UTC